Proteome Sciences PLC Milestone Payment for TMT(R)/TMTpro(TM) Sales (7307L)
05 Enero 2023 - 1:00AM
UK Regulatory
TIDMPRM
RNS Number : 7307L
Proteome Sciences PLC
05 January 2023
Prior to publication, the information contained within this
announcement was deemed by the Company to constitute inside
information as stipulated under the UK Market Abuse Regulation.
With the publication of this announcement, this information is now
considered to be in the public domain
5 January 2023
Proteome Sciences plc
("Proteome Sciences" or the "Company")
Milestone Payment for TMT(R)/TMTpro(TM) Sales
The Company announces that pursuant to the exclusive licence and
distributor agreement with Thermo Scientific, a cumulative sales
milestone has been achieved by Thermo Scientific. Pursuant to the
sales milestone, a milestone payment of GBP0.87m has been received
by the Company and will be recognised in the 2022 financial
year.
For further information please contact:
Proteome Sciences plc
Dr Mariola Soehngen, Chief Executive Tel: +44 (0)20 7043 2116
Officer
Dr Ian Pike, Chief Scientific Officer
Richard Dennis, Chief Commercial Officer
Abdelghani Omari, Chief Financial Officer
Allenby Capital Limited (AIM Nominated Adviser & Broker)
John Depasquale / Jeremy Porter (Corporate Tel: +44 (0) 20 3328 5656
Finance)
Tony Quirke (Sales)
About Proteome Sciences plc. ( www.proteomics.com )
Proteome Sciences plc is a specialist provider of contract
proteomics services to enable drug discovery, development and
biomarker identification, and employs proprietary workflows for the
optimum analysis of tissues, cells and body fluids. SysQuant(R) and
TMT(R) MS2 are unbiased methods for identifying and contextualising
new targets and defining mechanisms of biological activity, while
analysis using Super-Depletion and TMTcalibrator(TM) provides
access to over 8,500 circulating plasma proteins for the discovery
of disease-related biomarkers. Targeted assay development using
mass spectrometry delivers high sensitivity, interference-free
biomarker analyses in situations where standard ELISA assays are
not available.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCKZGGMMDLGFZZ
(END) Dow Jones Newswires
January 05, 2023 02:00 ET (07:00 GMT)
Proteome Sciences (AQSE:PRM.GB)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Proteome Sciences (AQSE:PRM.GB)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024